Michael Koenen‐Bergmann

Author

Boehringer Ingelheim (Germany)

Also Known As

Michael Koenen-Bergmann, Michael Koenen‐Bergmann

Publications

704

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United States)Hôpital Cochin Johns Hopkins University University of Liverpool

About

Michael Koenen‐Bergmann is an author at Boehringer Ingelheim (Germany) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	177
2	Health Sciences	1	1	55
3	Allergy	1	1	82
4	Biomedical Engineering	1	1	21
5	Immunology	1	1	19

Michael Koenen‐Bergmann

Publications

702

Citations

H-Index

Page 1

	Year	Citations
Tiotropium Respimat Inhaler and the Risk of Death in COPD Robert A. Wise, Antonio Anzueto, Ronald Dahl, New England Journal of Medicine	2013	332
Decrease in the oral bioavailability of dabigatran etexilate after co‐medication with rifampicin Sebastian Härtter, Michael Koenen‐Bergmann, Ashish Sharma, British Journal of Clinical Pharmacology	2012	117
Tiotropium Respimat Inhaler and the Risk of Death in COPD Robert A. Wise, Antonio Anzueto, Ronald Dahl, Survey of Anesthesiology AsthmaStudy Author InformationAllergyRadiological SciencesTiotropium Respimat Inhaler	2014	82
Surgical Stimulation Shifts EEG Concentration–Response Relationship of Desflurane Heiko Röpcke, Benno Rehberg, Michael Koenen‐Bergmann, Anesthesiology	2001	76
The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale Robert A. Wise, Antonio Anzueto, Peter M.A. Calverley, Respiratory Research Patient SafetyClinical TrialsRespimat® TrialLarge ScaleMedicine	2013	55
Population In Vitro-In Vivo Correlation Model for Pramipexole Slow-Release Oral Formulations Elena Soto, Sebastian Haertter, Michael Koenen‐Bergmann, Pharmaceutical Research Pharmaceutical ScienceExcipientsMedicinePharmacotherapyBiomedical Engineering	2009	21
Pharmacokinetic and Safety Evaluation of BILR 355, a Second-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers Fenglei Huang, Michael Koenen‐Bergmann, Thomas R. MacGregor, Antimicrobial Agents and Chemotherapy ImmunologyPharmacotherapyAntiviral DrugTranslational PharmacologyDrug Resistance	2008	19

Page 1